Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel(Princess Margaret Cancer Centre), Martha M. Kirstein(University of Lübeck), Anna Saborowski(Medizinische Hochschule Hannover), Stefan Boeck(German Cancer Research Center), Lutz Jacobasch(Orthopädische Praxis), Daniel Pink(Universitätsmedizin Greifswald), Danmei Zhang(Ludwig-Maximilians-Universität München), Johannes Mohm(University Hospital Carl Gustav Carus), Ullrich Graeven(Kliniken Maria Hilf), Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Nicolas Ziegenhagen(Helios Hospital Berlin-Buch), Albrecht Kretzschmar(Roche (Switzerland)), Eray Gökkurt(University Cancer Center Hamburg), Henning Wege(Universität Hamburg), Christian Lerchenmüller, Thorsten Götze(Goethe University Frankfurt), Gunnar Folprecht(University Hospital Carl Gustav Carus), Patrick Wenzel(TUM Klinikum), Philipp Schütt(OncoRay), Sebastian Belle(Heidelberg University)
Cited by 51
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k